# Clinical trial results:
# Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

## Summary

| | |
|---|---|
| EudraCT number | 2021-003450-22 |
| Trial protocol | SE IT ES |
| Global end of trial date | 31 January 2024 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 01 May 2024 |
| First version publication date | 01 May 2024 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | P-105-303 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT05179057 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | AlloVir, Inc. |
| Sponsor organisation address | 1100 Winter Street, Waltham, United States, MA 02451 |
| Public contact | Clinical Trials Information Line, AlloVir, Inc., +1 617-433-2605, ClinicalTrials@allovir.com |
| Scientific contact | Clinical Trials Information Line, AlloVir, Inc., +1 617-433-2605, ClinicalTrials@allovir.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 31 January 2024 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 31 January 2024 |
| Was the trial ended prematurely? | Yes |

Notes:

## General information about the trial

Main objective of the trial:

The main objectives of the study were:
- To compare the percent of participants who have clearance of adenovirus viremia at Day 29 in participants receiving posoleucel and standard of care (SoC) to that in participants receiving placebo and SoC.
- To determine the safety and tolerability of posoleucel by analyzing the incidence and severity of treatment-emergent adverse events (TEAEs), including individual adverse events of special interest (AESIs).

Protection of trial subjects:

This study was performed in compliance with the principles of Good Clinical Practice, including the archiving of essential documents.

Background therapy:

Participants in both treatment arms continued to receive SoC per their treating physician.

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 26 April 2022 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Canada: 6 |
| Country: Number of subjects enrolled | United Kingdom: 21 |
| Country: Number of subjects enrolled | United States: 17 |
| Country: Number of subjects enrolled | Italy: 9 |
| Country: Number of subjects enrolled | Spain: 3 |
| Country: Number of subjects enrolled | Sweden: 1 |
| Worldwide total number of subjects | 57 |
| EEA total number of subjects | 13 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|---|---|
| Infants and toddlers (28 days-23 months) | 6 |
| Children (2-11 years) | 28 |
| Adolescents (12-17 years) | 13 |
| Adults (18-64 years) | 8 |
| From 65 to 84 years | 2 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 47 study centers in the United States, Canada, Italy, Spain, Sweden, and the United Kingdom, and participated from April 2022 to January 2024.

### Pre-assignment

Screening details:

Participants with adenovirus infection receiving standard of care following allogeneic hematopoietic stem cell transplant (allo-HCT) were randomized in a 1:1 ratio to receive either posoleucel or placebo. Randomization was stratified by level of viremia (≥10,000 copies/mL or <10,000 copies/mL adenovirus DNA) and age (≥12 years or <12 years).

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Subject |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Posoleucel, Then Placebo |

Arm description:

Participants were randomized to receive 2 sequential infusions of posoleucel, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to placebo treatment between Day 29 and Week 10. In the Cross-Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3 days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Posoleucel |
| Investigational medicinal product code | ALVR105 |
| Other name | PSL, ALVR-105, Viralym-M |
| Pharmaceutical forms | Dispersion for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered as 2-4 milliliter infusion, visually identical to placebo.

| | |
|---|---|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Dispersion for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered as 2-4 milliliter infusion, visually identical to Posoleucel.

| | |
|---|---|
| **Arm title** | Placebo, Then Posoleucel |

Arm description:

Participants were randomized to receive 2 sequential infusions of placebo, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to posoleucel treatment between Day 29 and Week 10. In the Cross- Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3

days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Posoleucel |
| Investigational medicinal product code | ALVR105 |
| Other name | PSL, ALVR-105, Viralym-M |
| Pharmaceutical forms | Dispersion for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered as 2-4 milliliter infusion, visually identical to placebo.

| | |
|---|---|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Dispersion for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered as 2-4 milliliter infusion, visually identical to Posoleucel.

| **Number of subjects in period 1** | Posoleucel, Then Placebo | Placebo, Then Posoleucel |
|---|---|---|
| Started | 30 | 27 |
| Received Primary Study Treatment | 28 | 23 |
| Met Crossover Eligibility Criteria | 4 [1] | 5 [2] |
| Received Cross-over Treatment | 4 [3] | 5 [4] |
| Completed | 10 | 13 |
| Not completed | 20 | 14 |
| Study terminated | 13 | 7 |
| Discontinuation or withdrawal | 2 | 2 |
| Adverse event, non-fatal | 3 | 2 |
| Never received study treatment | 1 | 3 |
| Noncompliance with protocol | 1 | - |

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The milestone represents participants who met the cross-over eligibility criteria.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The milestone represents participants who received any cross-over treatment.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The milestone represents participants who received any cross-over treatment.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The milestone represents participants who met the cross-over eligibility criteria.

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Posoleucel, Then Placebo |

Reporting group description:

Participants were randomized to receive 2 sequential infusions of posoleucel, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to placebo treatment between Day 29 and Week 10. In the Cross-Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3 days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| Reporting group title | Placebo, Then Posoleucel |
|---|---|

Reporting group description:

Participants were randomized to receive 2 sequential infusions of placebo, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to posoleucel treatment between Day 29 and Week 10. In the Cross- Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3 days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| Reporting group values | Posoleucel, Then Placebo | Placebo, Then Posoleucel | Total |
|---|---|---|---|
| Number of subjects | 30 | 27 | 57 |
| Age categorical<br>Units: Subjects | | | |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 16.2 | 14.9 | |
| standard deviation | ± 17.10 | ± 15.80 | - |
| Gender categorical<br>Units: Subjects | | | |
| Female | 9 | 11 | 20 |
| Male | 21 | 16 | 37 |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or Latino | 5 | 2 | 7 |
| Not Hispanic or Latino | 22 | 23 | 45 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race<br>Units: Subjects | | | |
| Asian | 3 | 2 | 5 |
| Black or African American | 3 | 1 | 4 |
| White | 19 | 20 | 39 |
| Not Reported | 3 | 1 | 4 |
| Other | 2 | 3 | 5 |

## End points

### End points reporting groups

| Reporting group title | Posoleucel, Then Placebo |
|---|---|

Reporting group description:

Participants were randomized to receive 2 sequential infusions of posoleucel, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to placebo treatment between Day 29 and Week 10. In the Cross-Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3 days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| Reporting group title | Placebo, Then Posoleucel |
|---|---|

Reporting group description:

Participants were randomized to receive 2 sequential infusions of placebo, separated by 14 ± 3 days. The Primary Study Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

Eligible participants who experienced progression to active target organ disease or progression of existing target organ disease could cross-over to posoleucel treatment between Day 29 and Week 10. In the Cross- Over Period, participants received 2 sequential infusions of placebo, separated by 14 ± 3 days. The Cross-over Period included a 4-week efficacy evaluation followed by a 20-week safety follow-up.

| Subject analysis set title | Posoleucel (Primary Study Period) |
|---|---|
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants were randomized to receive 2 sequential infusions of posoleucel, separated by 14 ± 3 days, during the Primary Study Period.

| Subject analysis set title | Placebo (Primary Study Period) |
|---|---|
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants were randomized to receive 2 sequential infusions of placebo, separated by 14 ± 3 days, during the Primary Study Period.

| Subject analysis set title | Posoleucel (Cross-over Period) |
|---|---|
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants were randomized to receive 2 sequential infusions of placebo in the Primary Study Period and were eligible to cross-over between Day 29 and Week 10. Participants received posoleucel during the Crossover Period.

| Subject analysis set title | Placebo (Cross-over Period) |
|---|---|
| Subject analysis set type | Safety analysis |

Subject analysis set description:

Participants were randomized to receive 2 sequential infusions of posoleucel in the Primary Study Period and were eligible to cross-over between Day 29 and Week 10. Participants received placebo during the Cross-over Period.

### Primary: Number of Participants With Undetectable Adenovirus Infection

| End point title | Number of Participants With Undetectable Adenovirus Infection |
|---|---|

End point description:

Viral load of adenovirus was measured at the central laboratory using quantitative polymerase chain reaction (qPCR) from blood and stool samples at each study visit and on Day 29 from a nasopharyngeal swab. There was a 14-day window for participants who crossed over from posoleucel to placebo; and for participants who crossed over from placebo to posoleucel, the pre-dose cross-over Day 1 viral load was used. Participants missing the primary endpoint but having undetectable viremia before Day 29 and after Day 43 were imputed as successes. Undetectable adenovirus viremia was less than the lower limit of quantification (LLOQ).

The modified intent-to-treat (mITT) population included all randomized participants who received at

least one dose of posoleucel or placebo. Only participants in the mITT population who completed through Day 29 or discontinued early were included.

| End point type | Primary |
|---|---|

End point timeframe:

Day 29 through Day 43 (Day 29 + 14 days; up to 43 days post-first infusion)

| **End point values** | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 25 | 21 | | |
| Units: participants | 11 | 9 | | |

### Statistical analyses

| **Statistical analysis title** | Posoleucel versus Placebo |
|---|---|

Statistical analysis description:

A logistic regression model included treatment, level of viremia at baseline (≥10,000 copies/mL or <10,000 copies/mL adenovirus DNA), age (≥12 years or <12 years), and absolute lymphocyte counts at baseline. The null hypothesis is that the true percentage for posoleucel plus SoC is less than or equal to the true percentage for placebo plus SoC, and the alternative hypothesis is that it is greater.

| Comparison groups | Posoleucel, Then Placebo v Placebo, Then Posoleucel |
|---|---|
| Number of subjects included in analysis | 46 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0.98 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.26 |
| upper limit | 3.69 |

### Primary: Number of Participants Who Experienced TEAEs

| End point title | Number of Participants Who Experienced TEAEs[1] |
|---|---|

End point description:

A TEAE was defined as an adverse event (AE) with a start date and time on or after the first dose of study treatment. A serious AE (SAE) was an AE that met at least one of the following serious criteria: fatal, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; or other important medical event. Treatment-emergent AESI included acute or chronic graft versus host disease, cytokine release syndrome, infusion-related reactions, and graft failure or rejection. Treatment-related refers to the assessment of a relationship between study treatment and the event by the investigator.

The safety population included all participants who received any amount of posoleucel or placebo and had at least one post-treatment safety assessment.

| End point type | Primary |
|---|---|

End point timeframe:

Up to 34 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This was a pre-specified endpoint in which descriptive statistics were planned, with no hypothesis testing.

| **End point values** | Posoleucel (Primary Study Period) | Placebo (Primary Study Period) | Posoleucel (Cross-over Period) | Placebo (Cross-over Period) |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 28 | 23 | 5 | 4 |
| Units: participants | | | | |
| Any TEAE | 27 | 23 | 5 | 3 |
| Any TEAE related to study treatment | 7 | 9 | 1 | 1 |
| Any AESI | 6 | 9 | 1 | 2 |
| Any SAE | 16 | 16 | 3 | 1 |
| Any SAE related to study treatment | 1 | 1 | 1 | 1 |
| TEAE leading to study treatment discontinuation | 2 | 1 | 0 | 2 |
| Any TEAE leading to study discontinuation | 1 | 2 | 0 | 1 |
| Any TEAE leading to death | 2 | 1 | 0 | 1 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Overall Disease Progression

| End point title | Number of Participants With Overall Disease Progression |
|---|---|

End point description:

Data not collected due to early termination after Data and Safety Monitoring Board (DSMB) futility analysis concluded the study was unlikely to meet its primary endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

From Day 29 up to Week 10

| **End point values** | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[2] | 0[3] | | |
| Units: participants | | | | |

Notes:

[2] - Data not collected due to early termination after DSMB futility analysis.

[3] - Data not collected due to early termination after DSMB futility analysis.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area Under the Curve (AUC) Adenovirus Viral Load

| End point title | Area Under the Curve (AUC) Adenovirus Viral Load |
|---|---|

End point description:

Data not collected due to early termination after DSMB futility analysis concluded the study was unlikely to meet its primary endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose and Day 29

| End point values | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[4] | 0[5] | | |
| Units: copies/mL*h | | | | |
| arithmetic mean (standard deviation) | () | () | | |

Notes:

[4] - Data not collected due to early termination after DSMB futility analysis.

[5] - Data not collected due to early termination after DSMB futility analysis.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants Who Achieved Adenovirus Viremia <400 Copies/mL at Day 29

| End point title | Number of Participants Who Achieved Adenovirus Viremia <400 Copies/mL at Day 29 |
|---|---|

End point description:

Data not collected due to early termination after DSMB futility analysis concluded the study was unlikely to meet its primary endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 29

| End point values | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[6] | 0[7] | | |
| Units: participants | | | | |

Notes:

[6] - Data not collected due to early termination after DSMB futility analysis.

[7] - Data not collected due to early termination after DSMB futility analysis.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Undetectable Adenovirus Viremia (Less Than LLOQ)

| End point title | Time to Undetectable Adenovirus Viremia (Less Than LLOQ) |
|---|---|

End point description:

Data not collected due to early termination after DSMB futility analysis concluded the study was unlikely to meet its primary endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

Pre-dose to 34 weeks

| End point values | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[8] | 0[9] | | |
| Units: hours | | | | |
| median (full range (min-max)) | ( to ) | ( to ) | | |

Notes:

[8] - Data not collected due to early termination after DSMB futility analysis.

[9] - Data not collected due to early termination after DSMB futility analysis.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Adenovirus Disease Recurrence

| End point title | Number of Participants With Adenovirus Disease Recurrence |
|---|---|

End point description:

Data not collected due to early termination after DSMB futility analysis concluded the study was unlikely to meet its primary endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

34 weeks

| End point values | Posoleucel, Then Placebo | Placebo, Then Posoleucel | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[10] | 0[11] | | |
| Units: participants | | | | |

Notes:

[10] - Data not collected due to early termination after DSMB futility analysis.

[11] - Data not collected due to early termination after DSMB futility analysis.

### Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: Up to 34 weeks | |
| Assessment type | Systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 25.1 |

| Reporting groups | |
|---|---|
| Reporting group title | Posoleucel (Primary Study Period) |
| Reporting group description: Participants were randomized to receive 2 sequential infusions of posoleucel, separated by 14 ± 3 days, during the Primary Study Period. | |
| Reporting group title | Placebo (Primary Study Period) |
| Reporting group description: Participants were randomized to receive 2 sequential infusions of placebo, separated by 14 ± 3 days, during the Primary Study Period. | |
| Reporting group title | Posoleucel (Cross-over Period) |
| Reporting group description: Participants were randomized to receive 2 sequential infusions of placebo in the Primary Study Period and were eligible to cross-over between Day 29 and Week 10. Participants received posoleucel during the Crossover Period. | |
| Reporting group title | Placebo (Cross-over Period) |
| Reporting group description: Participants were randomized to receive 2 sequential infusions of posoleucel in the Primary Study Period and were eligible to cross-over between Day 29 and Week 10. Participants received placebo during the Cross-over Period. | |

| Serious adverse events | Posoleucel (Primary Study Period) | Placebo (Primary Study Period) | Posoleucel (Cross-over Period) |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 16 / 28 (57.14%) | 16 / 23 (69.57%) | 3 / 5 (60.00%) |
| number of deaths (all causes) | 2 | 1 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Leukaemia recurrent | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Capillary leak syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Disease progression | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 28 (14.29%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 6 | 1 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Acute graft versus host disease | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute graft versus host disease in intestine | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute graft versus host disease in skin | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic graft versus host disease | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic graft versus host disease in intestine | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic graft versus host disease in lung | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic graft versus host disease oral | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Graft versus host disease | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Graft versus host disease in gastrointestinal tract | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemophagocytic lymphohistiocytosis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Respiratory, thoracic and mediastinal disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 3 / 3 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal inflammation | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumomediastinum | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Lower limb fracture | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Autoimmune haemolytic anaemia | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemolytic anaemia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombotic microangiopathy | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune-mediated cytopenia | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Ascites | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Acute hepatic failure | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Hepatic failure | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal tubular disorder | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| COVID-19 | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cryptosporidiosis infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus colitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus infection reactivation | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia pyelonephritis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis rotavirus | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Human herpesvirus 6 infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Localised infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis viral | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Parainfluenzae virus infection | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Parotitis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Phlebitis infective | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumococcal bacteraemia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Placebo (Cross-over Period) | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Leukaemia recurrent | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Capillary leak syndrome | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Disease progression | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Acute graft versus host disease | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Acute graft versus host disease in intestine | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Acute graft versus host disease in skin | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic graft versus host disease | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic graft versus host disease in intestine | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic graft versus host disease in lung | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic graft versus host disease oral | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Graft versus host disease | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Graft versus host disease in gastrointestinal tract | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Haemophagocytic lymphohistiocytosis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory, thoracic and mediastinal disorders | | | | |
| Deep vein thrombosis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoxia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pharyngeal inflammation | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pleural effusion | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumomediastinum | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumothorax | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Investigations | | | | |
| Weight decreased | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Seizure | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Autoimmune haemolytic anaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemolytic anaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombotic microangiopathy | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune-mediated cytopenia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|---|---|---|
| Gastrointestinal disorders | | | |
| Ascites | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nausea | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Acute hepatic failure | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic failure | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Chronic kidney disease | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haematuria | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephrolithiasis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal tubular disorder | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infections and infestations | | | | |
| Bacteraemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| COVID-19 | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Candida infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Clostridium difficile colitis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Clostridium difficile infection | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cryptosporidiosis infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cytomegalovirus colitis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cytomegalovirus infection reactivation | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Device related infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enterocolitis infectious | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Escherichia pyelonephritis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis rotavirus | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Human herpesvirus 6 infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Localised infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis viral | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Parainfluenzae virus infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Parotitis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Phlebitis infective | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumococcal bacteraemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory syncytial virus infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sepsis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sinusitis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolism and nutrition disorders | | | | |
| Electrolyte imbalance | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypokalaemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypophosphataemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolic acidosis | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Posoleucel (Primary Study Period) | Placebo (Primary Study Period) | Posoleucel (Cross-over Period) |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 27 / 28 (96.43%) | 23 / 23 (100.00%) | 5 / 5 (100.00%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 4 / 28 (14.29%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 10 / 28 (35.71%) | 8 / 23 (34.78%) | 1 / 5 (20.00%) |
| occurrences (all) | 10 | 8 | 1 |
| Immune system disorders | | | |
| Acute graft versus host disease in intestine | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Acute graft versus host disease in skin | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Cytokine release syndrome | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Graft versus host disease | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Graft versus host disease in liver | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 1 | 1 |
| Hypoxia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tachypnoea | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Blood bicarbonate decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 28 (3.57%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 1 | 1 |
| Enterobacter test positive | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 3 / 23 (13.04%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 3 | 1 |
| Weight decreased | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Injury, poisoning and procedural complications | | | |
| Traumatic haematoma | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Congenital, familial and genetic disorders | | | |
| Phimosis | | | |
| subjects affected / exposed | 4 / 28 (14.29%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Cardiac disorders | | | |

| | | | |
|---|---|---|---|
| Pericardial effusion | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nervous system disorders | | | |
| Somnolence | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 28 (21.43%) | 5 / 23 (21.74%) | 2 / 5 (40.00%) |
| occurrences (all) | 6 | 5 | 2 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Eye disorders | | | |
| Orbital haematoma | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 6 / 28 (21.43%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 6 | 2 | 0 |
| Ascites | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|---|---|---|---|
| Constipation | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 5 / 28 (17.86%) | 4 / 23 (17.39%) | 1 / 5 (20.00%) |
| occurrences (all) | 5 | 4 | 1 |
| Gastritis | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 6 / 28 (21.43%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 8 / 28 (28.57%) | 4 / 23 (17.39%) | 0 / 5 (0.00%) |
| occurrences (all) | 8 | 4 | 0 |
| Hepatobiliary disorders | | | |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dry skin | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 3 | 1 | 1 |
| Renal and urinary disorders | | | |

| | | | |
|---|---|---|---|
| Dysuria | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Glycosuria | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Proteinuria | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Infections and infestations | | | |
| Adenoviral hepatitis | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Adenovirus infection | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| BK virus infection | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|---|---|---|---|
| COVID-19 | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Cytomegalovirus infection reactivation | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 3 / 23 (13.04%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 3 | 1 |
| Cytomegalovirus viraemia | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Enterovirus infection | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Epstein-Barr viraemia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Epstein-Barr virus infection reactivation | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Gastroenteritis adenovirus | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Klebsiella bacteraemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Klebsiella infection | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Rhinovirus infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 28 (7.14%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 3 | 0 |
| Sepsis | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Viral rhinitis | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 2 / 23 (8.70%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 2 | 1 |
| Hyperammonaemia | | | |
| subjects affected / exposed | 0 / 28 (0.00%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 28 (3.57%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hypermagnesaemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 0 / 23 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypervolaemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 1 | 1 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 2 / 23 (8.70%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 2 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 9 / 28 (32.14%) | 6 / 23 (26.09%) | 1 / 5 (20.00%) |
| occurrences (all) | 9 | 6 | 1 |

| | | | |
|---|---|---|---|
| Hypomagnesaemia | | | |
| subjects affected / exposed | 5 / 28 (17.86%) | 3 / 23 (13.04%) | 0 / 5 (0.00%) |
| occurrences (all) | 5 | 3 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 3 / 28 (10.71%) | 2 / 23 (8.70%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Iron overload | | | |
| subjects affected / exposed | 2 / 28 (7.14%) | 1 / 23 (4.35%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |

| **Non-serious adverse events** | Placebo (Cross-over Period) | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 4 (75.00%) | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Immune system disorders | | | |
| Acute graft versus host disease in intestine | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Acute graft versus host disease in skin | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cytokine release syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Graft versus host disease | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Graft versus host disease in liver | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Reproductive system and breast disorders | | | |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Tachypnoea | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Investigations | | | |

| | | | |
|---|---|---|---|
| Activated partial thromboplastin time prolonged<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Blood bicarbonate decreased<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Blood bilirubin increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Enterobacter test positive<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Gamma-glutamyltransferase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Lipase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Neutrophil count decreased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Platelet count decreased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---|---|---|
| Traumatic haematoma<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Congenital, familial and genetic disorders<br>Phimosis<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Cardiac disorders<br>Pericardial effusion<br>subjects affected / exposed<br>occurrences (all)<br>Sinus tachycardia<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1<br>1 / 4 (25.00%)<br>1 | | |
| Nervous system disorders<br>Somnolence<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)<br>Febrile neutropenia<br>subjects affected / exposed<br>occurrences (all)<br>Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1<br>0 / 4 (0.00%)<br>0<br>0 / 4 (0.00%)<br>0 | | |
| Eye disorders<br>Orbital haematoma<br>subjects affected / exposed<br>occurrences (all)<br>Vision blurred<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1<br>0 / 4 (0.00%)<br>0 | | |
| Gastrointestinal disorders | | | |

| | | | |
|---|---|---|---|
| Abdominal distension<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Ascites<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Constipation<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Gastritis<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Gastrointestinal haemorrhage<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Nausea<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Stomatitis<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Vomiting<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Hepatobiliary disorders<br>Hypertransaminasaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|---|---|---|
| Dry skin<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Rash<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Rash maculo-papular<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Glycosuria<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Proteinuria<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Renal failure<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Endocrine disorders<br>Adrenal insufficiency<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Musculoskeletal and connective tissue disorders<br>Back pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Infections and infestations<br>Adenoviral hepatitis | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Adenovirus infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| BK virus infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Bacteraemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| COVID-19 | | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | | |
| occurrences (all) | 1 | | | |
| Candida infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Cytomegalovirus infection reactivation | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Cytomegalovirus viraemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Enterovirus infection | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Epstein-Barr viraemia | | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Epstein-Barr virus infection reactivation | | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | | |
| occurrences (all) | 1 | | | |
| Gastroenteritis adenovirus | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Klebsiella bacteraemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Klebsiella infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rhinovirus infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Viral rhinitis | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperammonaemia | | | |
| subjects affected / exposed | 1 / 4 (25.00%) | | |
| occurrences (all) | 1 | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 4 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|---|---|---|
| Hypermagnesaemia<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Hypervolaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Hypoalbuminaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Hypokalaemia<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | | |
| Hypomagnesaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Hypophosphataemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |
| Iron overload<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 17 December 2021 | Major revisions include:<br>- Labeled safety objectives and endpoints as primary.<br>- Added a requirement for participants who receive a third dose for recurrence to undergo safety follow-up for 20 weeks after the third dose of study treatment.<br>- Added a statement that participating sites will adhere to relevant safety standards.<br>- Added a statement that participants will be approached for enrollment in a long-term registry study.<br>- Provided additional guidance on permitted and prohibited medications and the recording of concomitant medications.<br>- Updated text surrounding study treatment discontinuation.<br>- Added the Intent-to-Treat Population.<br>- Deleted the Modified Intent-to-Treat Population.<br>- Updated the planned analysis of the primary efficacy endpoint to be analyzed based on logistic regression instead of Fisher's exact test.<br>- Provided justification for analysis of the primary efficacy endpoint at Day 29 and for durability of response assessments.<br>- Revised schedule of assessments.<br>- Provided details on interim analyses.<br>- Added additional guidance on post-infusion monitoring.<br>- Added a statement that all protocol amendments will be submitted to regulatory authorities and ethics committees/Institutional Review Boards as appropriate.<br>- Added a statement that in some jurisdictions, legally effective informed consent must be obtained from all legal guardians for minor participants.<br>- Provided guidance on estimating fraction of inspired oxygen. |
| 23 August 2022 | Major Revisions include:<br>- Revised the order and timing of Study Objectives and Endpoints.<br>- Revised Eligibility Criteria.<br>- Added flexibility in blood specimen testing to allow blood specimen results from local laboratory results to be used for confirmation of eligibility and dosing if Adenovirus viral load results from the central laboratory are not available.<br>- Expanded the screening window.<br>- Added clarifying information regarding premature Crossover.<br>- Added Data Safety Monitoring Board review and recommendation of preliminary safety data from 5 participants ≥1 and ≤6 years of age prior to enrolling participants under age 1.<br>- Statistical Updates.<br>- Added language regarding premedication with an antihistamine.<br>- Streamlined study drug administration and dosing instructions.<br>- Updated text to clarify that no subsequent infusion of blinded study treatment should occur in participants who develop new onset graft versus host disease (Grade >2) or worsening of graft versus host disease.<br>- Added Clarifying information regarding Target Disease Endpoint Definitions. |
| 21 September 2023 | Major Revisions include:<br>- Revised Eligibility Criteria.<br>- Revised Concomitant Medications.<br>- Analysis updates. |
| 30 November 2023 | Major Revisions include:<br>- Addition of Interim analysis (sample size re-estimation and futility analysis).<br>- Changes in Sample Size Determination.<br>- Changes in Primary Analysis. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was discontinued following a pre-planned DSMB futility analysis concluding that the study was unlikely to meet its primary endpoint, no safety concerns were identified.

Notes: